Cilengitide plus standard treatment in newly diagnosed glioblastoma with methylated MGMT (CENTRIC)
Glioblastoma
Enrolment: 545 · Results not recorded
Loading the evidence…
Drug · Integrin alpha-V/beta-3 antagonist; Integrin alpha-V/beta-5 antagonist (ANTAGONIST, direct interaction, disease efficacy true)
3 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Glioblastoma
Enrolment: 545 · Results not recorded
Glioblastoma Multiforme
Enrolment: 81 · Results not recorded
Glioblastoma · Gliosarcoma
Enrolment: 41 · Results not recorded
Prostate Cancer
Enrolment: 16 · Results not recorded
Acute Myeloid Leukemia
Enrolment: 70 · Results not recorded
Diffuse Intrinsic Pontine Glioma
Enrolment: 32 · Results not recorded
Renal Impairment
Enrolment: 32 · Results not recorded
Non Small Cell Lung Cancer
Enrolment: 14 · Results not recorded
Advanced Solid Tumor
Enrolment: 35 · Results not recorded
Breast Carcinoma · Solid Neoplasm
Enrolment: 13 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Intestinal ischaemia/reperfusion by superior mesenteric artery occlusion for 45 min followed by reperfusion, with tissues collected 4 h after reperfusion
cRGD reduced gut and lung injury scores by 70.6 and 60.0 per cent, cut gut and lung myeloperoxidase by 77.8 and 54.2 per cent, lowered serum TNF-alpha and IL-6 by 71.0 and 67.9 per cent and reduced lung TUNEL-positive cells by 59.5 per cent.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.